CA3257926A1 - TREATMENT METHOD USING MAZDUTIDE - Google Patents
TREATMENT METHOD USING MAZDUTIDEInfo
- Publication number
- CA3257926A1 CA3257926A1 CA3257926A CA3257926A CA3257926A1 CA 3257926 A1 CA3257926 A1 CA 3257926A1 CA 3257926 A CA3257926 A CA 3257926A CA 3257926 A CA3257926 A CA 3257926A CA 3257926 A1 CA3257926 A1 CA 3257926A1
- Authority
- CA
- Canada
- Prior art keywords
- weeks
- target compound
- administering
- patient
- weekly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210622648.7 | 2022-06-01 | ||
| CN202210622648 | 2022-06-01 | ||
| PCT/CN2023/093311 WO2023231730A2 (zh) | 2022-06-01 | 2023-05-10 | 使用mazdutide的治疗方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3257926A1 true CA3257926A1 (en) | 2025-04-09 |
Family
ID=89026916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3257926A Pending CA3257926A1 (en) | 2022-06-01 | 2023-05-10 | TREATMENT METHOD USING MAZDUTIDE |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250296973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4534095A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025518227A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250021331A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119584980A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023281591A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3257926A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023231730A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202617173A (zh) * | 2021-06-25 | 2026-05-01 | 大陸商信達生物製藥(蘇州)有限公司 | Mazdutide的應用 |
| EP4788362A1 (en) * | 2023-10-03 | 2026-08-12 | Innovent Biologics (Suzhou) Co., Ltd. | Methods of treating diabetes and obesity |
| WO2026002224A1 (en) * | 2024-06-27 | 2026-01-02 | Innovent Biologics (Suzhou) Co., Ltd. | Method of treating polycystic ovary syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| US11419918B2 (en) * | 2017-11-06 | 2022-08-23 | Shenzhen Turier Biotech Co., Ltd. | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide |
| CN111423506B (zh) * | 2019-11-08 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种glp-1化合物 |
| TW202617173A (zh) * | 2021-06-25 | 2026-05-01 | 大陸商信達生物製藥(蘇州)有限公司 | Mazdutide的應用 |
-
2023
- 2023-05-10 AU AU2023281591A patent/AU2023281591A1/en active Pending
- 2023-05-10 CA CA3257926A patent/CA3257926A1/en active Pending
- 2023-05-10 KR KR1020247042558A patent/KR20250021331A/ko active Pending
- 2023-05-10 JP JP2024570699A patent/JP2025518227A/ja active Pending
- 2023-05-10 CN CN202380042982.8A patent/CN119584980A/zh active Pending
- 2023-05-10 EP EP23814915.7A patent/EP4534095A4/en active Pending
- 2023-05-10 US US18/869,519 patent/US20250296973A1/en active Pending
- 2023-05-10 WO PCT/CN2023/093311 patent/WO2023231730A2/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20250296973A1 (en) | 2025-09-25 |
| AU2023281591A1 (en) | 2025-01-02 |
| KR20250021331A (ko) | 2025-02-12 |
| EP4534095A2 (en) | 2025-04-09 |
| EP4534095A4 (en) | 2026-05-27 |
| CN119584980A (zh) | 2025-03-07 |
| WO2023231730A3 (zh) | 2024-01-25 |
| WO2023231730A2 (zh) | 2023-12-07 |
| JP2025518227A (ja) | 2025-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250296973A1 (en) | Treatment method using mazdutide | |
| EP4360641A1 (en) | Use of mazdutide | |
| JPH01233227A (ja) | 高インシュリン症の二次効果治療及び予防用医薬組成物 | |
| US20210052703A1 (en) | Glp-1 composition for treating obesity and weight management | |
| CN101631558A (zh) | 基于艾塞那肽和达拉根的用于治疗糖尿病的药物、其用途和治疗模式 | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| JP2023510609A (ja) | Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法 | |
| HK40118093A (en) | Treatment method using mazdutide | |
| WO2024243243A9 (en) | Treatment of adults with overweight or obesity with or without weight-related comorbidities | |
| HU193522B (en) | Process for producing pharmaceutical preparations containing human proinsulin | |
| KR20110052990A (ko) | 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법 | |
| HK40110048A (en) | Use of mazdutide | |
| KR20250095833A (ko) | 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법 | |
| WO2026037397A1 (zh) | Glp-1类似物的医药用途 | |
| US20260069586A1 (en) | Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome | |
| WO2026046202A1 (zh) | Glp-1/gip肽或含有其的药物组合物的用途 | |
| RU2834226C2 (ru) | Композиция glp-1 для лечения ожирения и регулирования веса | |
| WO2025124473A1 (zh) | Glp-1类似物治疗代谢疾病的方法及医药用途 | |
| TW202140061A (zh) | 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑 | |
| HK40094446A (en) | Glp-1 dosing regimen | |
| TW202506170A (zh) | 糖尿病之治療 | |
| Johns et al. | Future Antidiabetic Drugs | |
| US20260034076A1 (en) | Compositions and methods for treating pancreatic disease including type 3c diabetes | |
| HK40039237A (en) | Glp-1 analogue beinaglutide composition for treating obesity and weight management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241129 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250304 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250304 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250319 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250319 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250409 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250427 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250428 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260418 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260418 |